Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor

Allogene Therapeutics, Inc.

Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.
Yoshiyama previously VP Finance & Controller at AN2 Therapeutics and CAO at Tricida.
Shareholders elected four Class III directors (DeYoung, Humer, Kazam, Mayo) to serve until 2027.
Advisory say-on-pay approved with 119.7M votes for, 16.3M against.
Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2024.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Geoffrey Parker

principal accounting officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2024-06-05
Filed: June 10, 2024, 7:59 PM ET

Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.

Appointed

Annie Yoshiyama

principal accounting officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2024-06-05
Filed: June 10, 2024, 7:59 PM ET

appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Geoffrey Parker changed role as principal accounting officer at Allogene Therapeutics, Inc..

Action: replaced
Role: principal accounting officer

Exact text from the filing

Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Annie Yoshiyama was appointed as principal accounting officer at Allogene Therapeutics, Inc..

Action: appointed
Role: principal accounting officer

Exact text from the filing

appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity.

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.